Impaired liver function and long-term prognosis after hepatectomy for hepatocellular carcinoma

1995 ◽  
Vol 19 (3) ◽  
pp. 439-443 ◽  
Author(s):  
Motoshi Yasui ◽  
Akio Harada ◽  
Akihito Torii ◽  
Akimasa Nakao ◽  
Toshiaki Nonami ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Function ◽  
Impaired Liver Function ◽  
Impaired Liver ◽  
Long Term Prognosis

scholarly journals Survival Benefits of Small Anatomical Resection of the Liver for Patients with Hepatocellular Carcinoma and Impaired Liver Function, Based on New-Era Imaging Studies

2016 ◽  
Vol 7 (9) ◽  
pp. 1029-1036 ◽  
Author(s):  
Masahiko Sakoda ◽  
Shinichi Ueno ◽  
Satoshi Iino ◽  
Kiyokazu Hiwatashi ◽  
Koji Minami ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Function ◽  
Anatomical Resection ◽  
Imaging Studies ◽  
Impaired Liver Function ◽  
New Era ◽  
Resection Of The Liver ◽  
Impaired Liver

scholarly journals Surgical treatment strategy for hepatocellular carcinoma in patients with impaired liver function: hepatic resection or radiofrequency ablation?

HPB ◽  
2018 ◽  
Vol 20 (3) ◽  
pp. 244-250 ◽  
Author(s):  
Takanobu Yamao ◽  
Katsunori Imai ◽  
Yo-ichi Yamashita ◽  
Takayoshi Kaida ◽  
Shigeki Nakagawa ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Surgical Treatment ◽  
Radiofrequency Ablation ◽  
Liver Function ◽  
Hepatic Resection ◽  
Treatment Strategy ◽  
Impaired Liver Function ◽  
Impaired Liver

Pharmacokinetic (PK) and clinical phase II trial of imatinib in patients with impaired liver function and advanced hepatocellular carcinoma (HCC)

2005 ◽  
Vol 23 (16_suppl) ◽  
pp. 4135-4135 ◽  
Author(s):  
F. Eckel ◽  
S. von Delius ◽  
M. Dobritz ◽  
F. Fend ◽  
C. Hosius ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Function ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Advanced Hepatocellular Carcinoma ◽  
Impaired Liver Function ◽  
Clinical Phase ◽  
Impaired Liver

Time to Transcatheter Arterial Chemoembolization Refractoriness in Patients with Hepatocellular Carcinoma in Kinki Criteria Stages B1 and B2

2017 ◽  
Vol 35 (6) ◽  
pp. 589-597 ◽  
Author(s):  
Tadaaki Arizumi ◽  
Tomohiro Minami ◽  
Hirokazu Chishina ◽  
Masashi Kono ◽  
Masahiro Takita ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Cancer ◽  
Liver Function ◽  
Transcatheter Arterial Chemoembolization ◽  
Time To Progression ◽  
Impaired Liver Function ◽  
Impaired Liver ◽  
Tace Treatment ◽  
Arterial Chemoembolization

Background: Transarterial chemoembolization (TACE) is recommended for patients with hepatocellular carcinoma (HCC) in Barcelona Clinic Liver Cancer (BCLC) stage B. However, because of the heterogeneity of HCC in BCLC stage B; various subclassification systems have been proposed to predict the prognosis of patients. Previously, we proposed the Kinki criteria for precise classification of HCC cases in BCLC stage B. In this study, we compared the time to TACE refractoriness in HCC patients with Kinki criteria substages B1 and B2-HCC. Summary: Between January 2006 and December 2013, 592 HCC patients (substage B1, n = 118; substage B2, n = 170) underwent TACE. Time to progression under TACE treatment was defined as the time to untreatable progression (TTUP). TTUP and changes in liver function were analyzed in patients with substages B1 and B2-HCC. The median TTUP was 25.7 months (95% CI 19.3-37.3) and 16.4 months (95% CI 13.1-20.2) in patients with substage B1-HCC and substage B2-HCC, respectively (p = 0.0050). In patients with substage B2-HCC, median Child-Pugh scores after the first TACE session was significantly different from those after third and fifth TACE sessions (first-third, p = 0.0020; first-fifth, p = 0.0008). Key Message: TACE refractoriness occurred earlier in patients with substage B2-HCC than those with substage B1-HCC; deterioration of liver function with repeated TACE was more obvious in HCC cases with stage-B1 tumor. Shorter TTUP and impaired liver function due to repeated TACE could be responsible for the shorter survival in patients with substage B2-HCC.

scholarly journals The preventive effect of the impaired liver function for antiemetic therapy against chemotherapy-induced nausea and vomiting in hepatocellular carcinoma patients

2017 ◽  
Vol 61 (3) ◽  
pp. 222-227 ◽  
Author(s):  
Tomohiro Nishikawa ◽  
Akira Asai ◽  
Norio Okamoto ◽  
Hidetaka Yasuoka ◽  
Ken Nakamura ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Function ◽  
Nausea And Vomiting ◽  
Antiemetic Therapy ◽  
Preventive Effect ◽  
Impaired Liver Function ◽  
Impaired Liver

Hepatic resection of hepatocellular carcinoma in cirrhotic livers: Is it unjustified in impaired liver function?

Surgery ◽  
1996 ◽  
Vol 120 (1) ◽  
pp. 34-39 ◽  
Author(s):  
Cheng-Chung Wu ◽  
Willam-Lin Ho ◽  
Da-Cheng Yeh ◽  
Chi-Ren Huang ◽  
Tse-Jia Liu ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Function ◽  
Hepatic Resection ◽  
Impaired Liver Function ◽  
Impaired Liver

Is Portal Vein Embolization Followed by Hepatectomy for Hepatocellular Carcinoma Justified in Patients with Impaired Liver Function?

2020 ◽  
Author(s):  
Katsunori Imai ◽  
Yo-ichi Yamashita ◽  
Yosuke Nakao ◽  
Takashi Matsumoto ◽  
Shotaro Kinoshita ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Function ◽  
Portal Vein ◽  
Portal Vein Embolization ◽  
Impaired Liver Function ◽  
Impaired Liver

Cholestasis is the Main Determinant of Abnormal CA 19–9 Levels in Patients with Liver Cirrhosis

2000 ◽  
Vol 15 (3) ◽  
pp. 226-230 ◽  
Author(s):  
E. Giannini ◽  
P. Borro ◽  
F. Botta ◽  
B. Chiarbonello ◽  
A. Fasoli ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Alkaline Phosphatase ◽  
Liver Cirrhosis ◽  
Liver Function ◽  
Univariate Analysis ◽  
Impaired Liver Function ◽  
Main Determinant ◽  
Clear Explanation ◽  
Impaired Liver ◽  
Cirrhotic Patients

Background/Aims Altered CA19–9 levels are commonly found in patients with liver cirrhosis though a clear explanation for this finding has not yet been given. The aim of this study was to investigate whether CA19–9 levels might be related to alterations in biochemical parameters and/or to functional impairment in cirrhotic patients with and without hepatocellular carcinoma. Methods: We studied 126 patients with liver cirrhosis, 60 of whom also had hepatocellular carcinoma. CA19–9 values were related to clinical, biochemical and functional parameters. In half of the patients CA19–9 levels were related to the monoethylglycinexylidide test, which is a dynamic liver function test. Results In more than half the cases CA19–9 values were above the upper limit. Liver function worsening as assessed by Child-Pugh's score and monoethylglycinexylidide test did not seem to influence the alteration of the marker. By contrast, in univariate analysis CA19–9 correlated with aminotransferases, γ-glutamyltransferase and alkaline phosphatase. Multivariate analysis showed that besides alkaline phosphatase also the presence of hepatocellular carcinoma might influence the alteration of CA19–9, although the marker was of no use for the diagnosis of liver cancer in patients with altered though not diagnostic α-fetoprotein levels. Conclusions In our study we confirmed the correlation of CA19–9 levels with cholestasis and cytolysis parameters. Moreover, we found no association between CA19–9 levels and impaired liver function as assessed by means of the Child-Pugh's score and the monoethylglycinexylidide test, which is cholestasis-independent and explores liver metabolic and clearance activities. The cholestatic picture that characterizes liver cirrhosis might enhance the expression and passage of the marker from the bile to the blood. The addition of CA19–9 assessment is not useful for the diagnosis of hepatocellular carcinoma in patients with non-diagnostic levels of α-fetoprotein. Caution should therefore be used when evaluating CA19–9 in cirrhotic patients with cholestasis, since false positive results may occur.

Sign in / Sign up

Export Citation Format

Share Document